<PAGE>   1

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                    CURRENT REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

      Date of Report (Date of earliest event reported): November 11, 1998



                                 NOVAVAX, INC.
                                 -------------
             (Exact name of registrant as specified in its charter)


           DELAWARE               0-26770            22-2816046
           --------               -------            ----------    
   (State of incorporation)     (Commission        (I.R.S. Employer
                                File Number)      Identification No.)


                     8320 GUILFORD ROAD, COLUMBIA, MD 21046
                     --------------------------------------            
                    (Address of principal executive offices)

                                 (301) 854-3900
                                 --------------   
               Registrant's telephone number, including area code



Item 5.     OTHER EVENTS

            On November 17, 1998, the Company announced the addition of Gary
Evans, Michael McManus and Denis O'Donnell, M.D. to the Board of Directors and
the addition of Ronald Kennedy, Ph.D. to the Scientific Advisory Board as more
fully discussed in the Press Release dated November 17, 1998 which is filed as 
Exhibit 99 to this Current Report on Form 8-K and incorporated by reference 
herein.



<PAGE>   2



Item 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

            (a) NA
            (b) NA
            (c) Exhibits:  The following exhibit is filed with this report:

                    Exhibit No.       Description
                    -----------       -----------
                    99                Press Release dated November 17, 1998


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.


                                          NOVAVAX, INC.


Date:   November 17, 1998                 By: /s/ Brenda L. Fugagli
                                          ------------------------------
                                          Brenda L. Fugagli
                                          Executive Vice President, Chief
                                          Operating Officer and Chief
                                          Financial Officer



EXHIBIT INDEX

Exhibit No.             Description
- -----------             -----------
99                      Press Release dated November 17, 1998






<PAGE>   1

NOVAVAX, INC. ANNOUNCES ADDITIONS TO THE BOARD OF 
DIRECTORS AND THE SCIENTIFIC ADVISORY BOARD

COLUMBIA, Md., Nov. 17 /PRNewswire/ -- Novavax, Inc. (Amex: NOX) today
announced the addition of Gary Evans, Michael McManus and Denis O'Donnell, M.D.,
to the Board of Directors and the addition of Ronald Kennedy, Ph.D. to the
Scientific Advisory Board.

Mr. Evans is founder of Magnum Hunter Resources, Inc. and has served as
President, CEO and a Director of the company since 1995. He also serves as CEO
of all of the Magnum Hunter Subsidiaries. Mr. Evans was a commercial banker for
nine years prior to his entry into the oil and gas business. He was an officer
of Mercantile Bank of Canada where he held various positions including VP and
Manager of the Energy Division of the Southwestern United States. As a senior
energy lending officer of a $5 billion Canadian bank, he initiated and managed
an energy loan portfolio of approximately $200 million. Mr. Evans serves on the
Board of Directors of Swanson Consulting Services, Inc., a Houston based
geological firm, and Karts International, Inc., a NASDAQ listed manufacturing
company. He also serves as a Trustee of TEL Offshore Trust, an OTC listed oil
and gas trust.

Mr. McManus is the President, CEO and a
 Director of Misonix, Inc., a developer,
manufacturer and marketer of medical, scientific, and industrial ultrasonic and
air pollution systems. He has had substantial experience in the areas of
healthcare, law, government, acquisitions and banking. He was most recently
President and Chief Executive Officer of New York Bancorp., a New York Stock
Exchange company that was one of the highest returning thrifts in the country.
He was responsible for growing that company from approximately $900 million to
$3.2 billion prior to its sale in March 1998. Prior to New York Bancorp., Mr.
McManus had served as Corporate Counsel and then as VP of Strategic Planning at
Pfizer Inc. From 1982 to 1985, he served as an Assistant to President Reagan in
the White House where he was responsible for planning and special events. Mr.
McManus holds a B.A. in Economics from the University of Notre Dame and a J.D.
from the Georgetown Law Center. He serves on the Board of Directors of the US
Olympic Committee, among others.

Dr. O'Donnell is the past President and COO of Novavax, holding those offices
until his taking the position as General Partner at Seaside Partners, LP, a
limited partnership focused on making equity investments in the small cap
sector, in 1997. Mr. O'Donnell continued as a Senior Advisor to Novavax through
June of 1998. Prior to his joining Novavax in 1995, Dr. O'Donnell was a Vice
President of IGI, Inc., Novavax's former parent company. In addition, Dr.
O'Donnell is a member of the Board of Directors of ELXSI, Inc., a member of the
Scientific Advisory Board of the Associates of Clinical Pharmacology and is a
Clinical Instructor of Health Science at Northeastern University, in Boston,
Massachusetts.

"At this point of our growth we felt that it was time to significantly expand
our board of directors," said Ronald H. Walker, Chairman of the Board at
Novavax. "With a strengthened board we believe we are now in a position to
identify and recruit a permanent CEO to continue the sustained fundamental
progress of the company."

"A strong board is a critical management resource," said Mitchell J. Kelly,
Interim President and CEO. "These new members bring a wealth of operational and
financial experience at a critical time in Novavax's growth."

In addition to the new members joining the Board of Directors, Dr. Ronald C.
Kennedy is a new addition to the Scientific Advisory Board. Dr. Kennedy is a
Professor in the Department of Microbiology and Immunology at the University of
Oklahoma Health Sciences Center. He received his B.A. degree in Microbiology
from Rutgers College and his M.S. and Ph.D. degrees in Microbiology from the
University of Hawaii. Following postdoctoral graduate training in Infectious
Disease and Cancer Research at Baylor




<PAGE>   2

College of Medicine in Houston, Texas, Dr. Kennedy was appointed to the faculty
as an Assistant Professor in the Department of Virology and Epidemiology in
1984. He subsequently moved to San Antonio, Texas, where he performed his
research activities at the Southwest Foundation for Biomedical Research and was
an Adjunct Professor in the Departments of Microbiology and Pediatrics at the
University of Texas Health Sciences Center at San Antonio. During his tenure in
San Antonio, Dr. Kennedy was also the Director of a federally funded Center for
AIDS Research. In 1994, he moved to Oklahoma City to assume his present
position. Dr. Kennedy serves and has previously served on a number of National
and International scientific boards and panels as well as to a number of
Biotechnology and Pharmaceutical Company Scientific Advisory Boards.

Novavax would like to thank General Wayne Downing (retired) who stepped down
from the board this fall following over two years of sharing his invaluable
experience with the company.

Novavax is a biopharmaceutical drug delivery company headquartered in Columbia,
Maryland. Its three strategic initiatives are hormone replacement therapies,
drug delivery partnerships and the development of anti-microbial technologies.
Novavax's two lead drug candidates in clinical development are proprietary,
topical, cosmetic-like cream formulations. ESTRASORB contains 17B estradiol for
the treatment of symptomatic, menopausal women, and ANDROSORB contains
testosterone for treating testosterone-deficient men.

Statements made in this press release that state the company's or management's
intentions, hopes, beliefs, expectations or predictions of the future are
forward-looking statements. The company's actual results could differ materially
from those projected in such forward-looking statements. Additional information
concerning factors that could cause actual results to differ materially from
those in the forward-looking statements is contained in Item 7 of the company's
SEC report on Form 10K/A for the year ended December 31, 1997 and the company's
report on Form 10-Q for the quarter ended September 30, 1998, incorporated
herein by reference. Statements made herein should be read in conjunction with
the company's Form 10K/A and Form 10-Q. Copies of these filings may be obtained
by contacting the company or the SEC. 8320 Guilford Road, Columbia, MD 21046 Tel
301-854-3900 Fax 301-854-3901. SOURCE Novavax, Inc.

(C) PR Newswire. All rights reserved.

ADDITIONAL SOURCES OF INFORMATION
Company Profile - From E*TRADE: NOX
Stock Charts - From Quote.Com: NOX
SEC Filings - From EDGAR Online: NOX
Company Capsule - From Hoover's Online: NOX
Quick Facts - From Market Guide: NOX